The use of monoclonal antibodies (mAbs) as therapeutics for different diseases (especially cancers) has increased rapidly over the past decades. As the long-term pioneer as well as market leader in the field of therapeutic antibody development, Creative Biolabs has successfully established and commercialized a wide spectrum of functional assays to illustrate antibody bioactivity and mechanism of action (MOA). Particularly, we offer antibody functional analysis services targeting specific receptors, including G protein-coupled receptors (GPCRs), immune checkpoints, and ion channels.

Antibodies Targeting Immune Checkpoints

Therapeutic antibodies can directly target molecules expressed on tumor cells to achieve their therapeutic effects through Fc-dependent cytotoxic effects. Alternatively, mAbs can target receptors of the immune system to promote anti-cancer immunity, so-called immunomodulatory mAbs. Immunomodulatory mAbs, when compared to traditional mAbs targeting tumor antigens, have shown different advantages, including (i) powerful tumor-specific T-cell responses with the hope of eliminating established tumors and (ii) generating long-term tumor immunity and developing immunological memory to the tumor.

Fig. 1 Therapeutic monoclonal antibodies targeting immune checkpoints in cancer therapy. (Marhelava, et al., 2019) Fig. 1 Therapeutic monoclonal antibodies targeting immune checkpoints in cancer therapy.1

Immunomodulatory mAbs can be either activatory (agonist) towards a stimulatory receptor by mimicking ligand engagement (immunostimulatory mAb) or inhibitory (antagonist) against a checkpoint blocker by blocking ligand engagement. With years of experience in the development of therapeutic mAbs targeting immune checkpoints, Creative Biolabs offers in vitro binding assays to assess the interaction between selected antibody candidates and their targeted immune checkpoint proteins (both activatory and inhibitory). Moreover, we can assess the immunomodulatory activity of antibodies by conducting T cell proliferation assay, cytokine production assay, and T cell cytotoxicity assay. These functional assays are sensitive, high-throughput, and reliable. For more information about these assays, please click the links below.

Antibodies Targeting GPCRs

GPCRs, which are seven-transmembrane receptors, are considered as the largest family of targets for approved drugs. Despite the wide utility of GPCR-targeted drugs, the generation of mAbs targeting GPCRs is difficult. With rich experience in antibody discovery and membrane protein studies, Creative Biolabs has established a cutting-edge platform for anti-GPCR membrane protein antibody discovery against a variety of GPCR targets. Moreover, backed by our extensive experience in antibody functional studies, Creative Biolabs is able to offer the most comprehensive GPCR-targeted functional assays for your antibody screening purposes. We focus on a wide spectrum of GPCR targets and we can offer customized GPCR stable cell line development services to better suit your requirements.

Antibodies Targeting Ion Channels

Ion channels are a large family of membrane proteins that function by allowing ionic passage across cellular membranes. They can play critical roles in physiology and disease by modulation of cellular functions such as electrical excitability, secretion, cell migration, and gene transcription. Therefore, ion channels represent an important target class for drug discovery, which is dominated by small molecules. Antibodies directed towards ion channels have the potential to offer many advantages compared with their small-molecule counterparts, including selectivity, bioavailability, and effector functions. With state-of-the-art technologies and years of experience in anti-ion channel antibody discovery, Creative Biolabs offers high-quality functional analysis for your antibody candidates targeting various ion channels, including voltage-gated potassium ion channels, calcium-activated potassium ion channels, voltage-gated sodium ion channels, etc.

Creative Biolabs has combined extensive knowledge and experience in therapeutic antibody exploitation with multiple state-of-the-art techniques and established a series of antibody function analysis services. We provide diverse assay formats and can guarantee our clients with the most compelling and reproducible outcomes, offering absolute confidence for subsequent investigations. For more detailed information, please feel free to contact us or directly sent us an inquiry.

Reference

  1. Marhelava, Katsiaryna, et al. "Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer." Cancers 11.11 (2019): 1756.

For Research Use Only.



Online Inquiry
Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
Contact Us USA

Tel:
Fax:
Email:
UK

Tel:
Email:

Germany

Tel:
Email:

Follow us on:
Copyright © 2024 Creative Biolabs.